Effect of Caffeine-Containing versus Decaffeinated Coffee on Serum Clozapine Concentrations in Hospitalised Patients

Basic and Clinical Pharmacology and Toxicology

Volumn 94, Issue 1, 2004, Pages 13-18

  Raaska, Kari ^a   Raitasuo, Virpi ^b   Laitila, Jouko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Kellokoski Hospital   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CAFFEINE; CLOZAPINE; CLOZAPINE N OXIDE; CYTOCHROME P450 1A2; NORCLOZAPINE; PARAXANTHINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COFFEE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; FEMALE; FOOD DRUG INTERACTION; HEREDITY; HOSPITAL PATIENT; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; BLOOD; DRUG ANTAGONISM; HOSPITALIZATION; METABOLISM; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; C-REACTIVE PROTEIN; CAFFEINE; CLOZAPINE; COFFEE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED;

EID: 1642285253     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2004.pto_940104.x     Document Type: Article

References (26)

1. Bertilsson, L., J. A. Carrillo, M.-L. Dahl, A. Llerena, C. Alm, U. Bondesson, L. Lindström, I. R. De La Rubia, S. Ramos & J. Benitez: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Brit. J. Clin. Pharmacol. 1994, 38, 471-473.
2. Butler, M. A., M. Iwasaki, F. P. Guengerich & F. F. Kadlubar: Human cytochrome P-450PA (P-450IA2), the phenacetin O-de-ethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 1989, 86, 7696-7700.
3. Carrillo, J. A. & J. Benitez: Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin. Pharmacol. Ther. 1994, 55, 293-304.
4. Carrillo, J. A. & J. Benitez: CYPIA2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br. J. Clin. Pharmacol 1996, 41, 605-608.
5. Carrillo, J. A., A. G. Herraiz, S. I. Ramos & J. Benitez: Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. Psychopharmacol. 1998, 18, 311-316.
6. Carrillo, J. A. & J. Benitez: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin. Pharmacokinet. 2000, 39, 127-153.
7. Hiemke, C., H. Weigmann, S. Hartter, N. Dahmen, H. Wetzel & H. Muller: Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 1994, 14, 279-281.
8. Holland, D. T., K. A. Godfredsen, T. Page & J. D. Connor: Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. J. Chromatogr. B Biomed. Sci. Appl. 1998, 707, 105-110.
9. Hughes, G. V. & F. J. Boland: The effects of caffeine and nicotine consumption on mood and somatic variables in a penitentiary inmate population. Addict. Behav. 1992, 17, 447-457.
10. Hughes, J. R., P. McHugh & S. Holtzman: Caffeine and schizophrenia. Psychiatr. Serv. 1998, 49, 1415-1417.
11. Hägg, S., O. Spigset, T. Mjörndal & R. Dahlqvist: Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Brit. J. Clin. Pharmacol. 2000, 49, 59-63.
12. Kaplan, G. B., D. J. Greenblatt, B. L. Ehrenberg, J. E. Goddard, M. M. Cotreau, J. S. Harmatz & R. I. Shader: Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J. Clin. Pharmacol. 1997, 37, 693-703.
13. Koponen, H., E. Leinonen & U. Lepola: Fluvoxamine increases the clozapine serum levels significantly. Eur. Neuropsychopharmacol. 1996, 6, 69-71.
14. Lindström, E., T. Lewander, U. Malm, U. F. Malt, H. Lublin & U. G. Ahlfors: Patient rated versus clinician rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU side effect rating scale (UKU-SERS-Pat). Nord. J. Psychiatry. 2001, 55 [Suppl 44], 5-69.
15. Mandel, H. G.: Update on caffeine consumption, disposition and action. Food Chem. Toxicol. 2002, 40, 1231-1234.
16. Markkola, L., J. Raussi & G.-B. Sulonen: A particle enhanced immunoturbidimetric assay of low CRP concentrations. Scand. J. Clin. Lab. Invest. 2000, 60 [Suppl232], 68-69.
17. Overall, J. E. & D. R. Gorham: DR (1962) Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10, 799-812.
18. Pickard, C. E., A. D. Stewart, R. Hartley & M. D. Lucock: A rapid HPLC method for monitoring plasma levels of caffeine and theophylline using solid phase extraction columns. Ann. Clin. Biochem. 1986, 23, 440-446.
19. Raaska, K. & P. J. Neuvonen: Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur. J. Clin. Pharmacol. 2000, 56, 585-589.
20. Raaska, K., V. Raitasuo & P. J. Neuvonen: Effect of influenza vaccination on serum clozapine and its main metabolite concentrations in patients with schizophrenia. Eur. J. Clin. Pharmacol. 2001, 57, 705-708.
21. Raaska, K., V. Raitasuo, M. Arstila & P. J. Neuvonen: Bacterial pneumonia can increase serum concentration of clozapine. Eur. J. Clin. Pharmacol. 2002, 58, 321-322.
22. Sato, J., H. Nakata, E. Owada, T. Kikuta, M. Umetsu & K. Ito: Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. Eur. J. Clin. Pharmacol. 1993, 44, 295-298.
23. Schulz, E., C. Fleischhaker & H. Remschmidt: Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiatry 1995, 28, 20-25.
24. Seppälä, N. H., E. V. J. Leinonen, M.-L. Lehtonen & K. T. Kivistö: Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacology & Toxicology 1999, 85, 244-246.
25. Weigmann, H. & C. Hiemke: Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 1992, 583, 209-216.
26. Özdemir, V., W. Kalow, P. Posner, E. J. Collins, J. L. Kennedy, B. K. Tang, L. J. Albers, C. Reist, R. Roy, W. Walkes & P. Afra: CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. J. Clin. Psychopharmacol. 2001, 21, 398-407.